VRTX
Vertex Pharmaceuticals Inc
NASDAQ: VRTX · HEALTHCARE · BIOTECHNOLOGY
$427.38
+0.98% today
Updated 2026-04-29
Market cap
$109.50B
P/E ratio
28.10
P/S ratio
9.12x
EPS (TTM)
$15.32
Dividend yield
—
52W range
$363 – $511
Volume
1.3M
Vertex Pharmaceuticals Inc (VRTX) Earnings
Quarterly earnings history, analyst estimates, and stock price reaction.
EPS beat streak
4 of 8
Last 8 quarters
Avg EPS surprise
+0.8%
Last 4 quarters
Revenue YoY growth
+10.8%
Most recent quarter
EPS YoY growth
+26.4%
Most recent quarter
Earnings surprise history (last 12 quarters)
Beat estimate Missed estimate
Quarterly EPS and revenue trend
Quarterly revenue EPS (diluted)
How the stock reacts to earnings
Avg 1-day reaction
-5.2%
Last 3 reports
Positive reaction rate
33%
1 of 3 quarters
Largest single-day move
-18.9%
2025-08-04
| Report date | EPS actual | Surprise | Close before | Close after | 1-day reaction |
|---|---|---|---|---|---|
| 2026-02-04 | $5.03 | -1.8% | $465.61 | $458.81 | -1.5% |
| 2025-11-10 | $4.80 | +4.1% | $409.47 | $429.22 | +4.8% |
| 2025-08-04 | $4.52 | +6.4% | $462.13 | $374.98 | -18.9% |
Quarterly earnings history
| Fiscal quarter ending | EPS estimate | EPS actual | Surprise | Revenue | YoY revenue |
|---|---|---|---|---|---|
| 2025-12-31 | $5.12 | $5.03 | -1.8% | $3.23B | +10.8% |
| 2025-09-30 | $4.61 | $4.80 | +4.1% | $3.08B | +11.0% |
| 2025-06-30 | $4.25 | $4.52 | +6.4% | $2.96B | +12.1% |
| 2025-03-31 | $4.29 | $4.06 | -5.4% | $2.77B | +3.1% |
| 2024-12-31 | $4.02 | $3.98 | -1.0% | $2.91B | +15.7% |
| 2024-09-30 | $4.13 | $4.38 | +6.1% | $2.77B | +11.6% |
| 2024-06-30 | $2.94 | $-12.83 | -536.4% | $2.65B | +6.1% |
| 2024-03-31 | $4.06 | $4.76 | +17.2% | $2.69B | +13.2% |
| 2023-12-31 | $4.10 | $4.20 | +2.4% | $2.52B | — |
| 2023-09-30 | $3.97 | $4.08 | +2.8% | $2.48B | — |
| 2023-06-30 | $3.88 | $3.89 | +0.3% | $2.49B | — |
| 2023-03-31 | $3.00 | $3.05 | +1.7% | $2.37B | — |
Analyst EPS and revenue estimates for upcoming years
| Period | EPS estimate | Revenue estimate | Revenue growth | Analysts | Confidence |
|---|---|---|---|---|---|
| 2026 (E) | $19.39 | $13.3B | +10.8% | 29 | high |
| 2027 (E) | $22.05 | $14.7B | +10.3% | 29 | high |
| 2028 (E) | $24.50 | $15.8B | +7.8% | 29 | medium |
| 2029 (E) | $26.80 | $16.9B | +7.0% | 29 | medium |
Frequently asked questions
Has Vertex Pharmaceuticals Inc beaten earnings estimates?
Vertex Pharmaceuticals Inc has beaten Wall Street EPS estimates in 4 of its last 8 quarterly reports, with an average EPS surprise of +0.8% over the last 4 quarters.
How does VRTX stock react to earnings?
VRTX stock has moved an average of -5.2% in the trading day following earnings over its last 3 reports, with positive reactions in 33% of those quarters.
What is Vertex Pharmaceuticals Inc's revenue growth rate?
Vertex Pharmaceuticals Inc reported year-over-year revenue growth of +10.8% in its most recent quarter, with EPS growing +26.4% year-over-year.
What is the expected EPS for VRTX in 2026?
Analysts expect Vertex Pharmaceuticals Inc to report EPS of $19.39 for fiscal year 2026, on revenue of $13.3B, based on estimates from 29 analysts.